Patricia Campbell's practice encompasses various aspects of IP law including patent prosecution, opinion work, IP due diligence, and patent litigation. She has particular experience in the pharmaceutical, chemical, and biotechnology sectors.

In addition to patent procurement and portfolio management, Patricia advises clients regarding patentability, validity, infringement, and freedom-to-operate issues and performs due diligence evaluations of patent portfolios for possible investment, licensing, or acquisition.

Her representative clients include AbbVie, Ambit, Amgen, Becton Dickinson, BioMarin Pharmaceutical, Celgene, Genentech, Idenix Pharmaceuticals, and Scynexis, as well as other start-up companies, established companies, academic institutions, and investment firms.

Prior to practicing law, Patricia was a tenured associate professor in the Department of Medicinal Chemistry at the University of Washington, where she served as principal investigator on research projects funded by the National Institutes of Health and the Department of Defense. Her research programs included structure-based design of a glycopeptide breast cancer vaccine and structural and kinetic studies probing the molecular mechanisms of cytochrome P450 allostery.